Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARQT Arcutis Biotherapeutics Inc.

Not Yet Opened 01-12 16:00:00 EST

26.78

-1.44

-5.10%

盘后26.40

-0.38-1.42%

19:30 EST

High28.10	Low25.45	Vol4.01M
Open27.75	D1 Closing28.22	Amplitude9.39%
Mkt Cap3.28B	Tradable Cap2.36B	Total Shares122.49M
T/O105.75M	T/O Rate4.54%	Tradable Shares88.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":26.78,"timestamp":1768251600000,"preClose":28.22,"halted":0,"volume":4007642,"hourTrading":{"tag":"盘后","latestPrice":26.4,"preClose":26.78,"latestTime":"19:30 EST","volume":418123,"amount":11196830.9988,"timestamp":1768264215441},"delay":0,"floatShares":88242300,"shares":122492192,"eps":-0.350649,"marketStatus":"Not Yet Opened","change":-1.44,"latestTime":"01-12 16:00:00 EST","open":27.75,"high":28.1,"low":25.45,"amount":105754667.02178401,"amplitude":0.093905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.350649,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":28.22,"preHourTrading":{"tag":"盘前","latestPrice":27.73,"preClose":28.22,"latestTime":"09:29 EST","volume":3557,"amount":99125.12434,"timestamp":1768228199999},"postHourTrading":{"tag":"盘后","latestPrice":26.4,"preClose":26.78,"latestTime":"19:30 EST","volume":418123,"amount":11196830.9988,"timestamp":1768264215441},"volumeRatio":2.432941,"impliedVol":0.308,"impliedVolPercentile":0.0279},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"2603575021","title":"Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603575021?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:37","pubTimestamp":1768271850,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $37.00. Ear covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-arcutis-biotherapeutics-arqt-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-arcutis-biotherapeutics-arqt-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","ARQT"],"gpt_icon":0},{"id":"2602548512","title":"BRIEF-Arcutis Highlights 2026 Strategic Priorities And Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548512","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:26","pubTimestamp":1768224370,"startTime":"0","endTime":"0","summary":"BRIEF-Arcutis Highlights 2026 Strategic Priorities And Anticipated MilestonesJan 12 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O:ARCUTIS HIGHLIGHTS 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTON","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5RYCPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2602510885","title":"Arcutis Biotherapeutics Projects 2026 ZORYVE Sales of $455-$470 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510885","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510885?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222830,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. has issued financial guidance for 2026, projecting full-year net product sales of ZORYVE  in the range of $455 to $470 million. This forecast reflects the company’s expectation of continued strong growth for ZORYVE, following a transformative year in 2025 in which the product solidified its position in the market for chronic inflammatory skin diseases. The transition to positive cash flows will enable Arcutis to further invest in expanding the ZORYVE franchise and advancing its pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the informati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLb2ZN58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","NDAQ","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","ARQT","LU2095319765.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2602510205","title":"Arcutis Biotherapeutics Inc - Topline Results From Integument-Infant Phase 2 Study Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510205?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5RYCPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2602510878","title":"Press Release: Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510878?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"-- Continued strong growth of ZORYVE  in 2026 with full-year. -- Advancement of ZORYVE indication-expansion strategy beginning with. ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis. -- Transition to positive cash flows enables investment to both accelerate. \"2025 was a transformative year as we solidified ZORYVE's position as an advanced targeted topical with the potential to redefine the standard of care for chronic inflammatory skin diseases,\" said Frank Watanabe, president and chief executive officer of Arcutis. \"In 2026, we will build on this momentum by driving ZORYVE growth across approved indications and investing in our commercial capabilities to accelerate the conversion from topical corticosteroids. At the same time, we will advance our innovative pipeline, including ZORYVE life cycle initiatives and ARQ-234, our biologic for atopic dermatitis. With strong operating leverage, we are well positioned to pursue new opportunities and reinforce our leadership ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT","R","BK4232","BK4022"],"gpt_icon":0},{"id":"2601330280","title":"Will ZORYVE-Driven 121.7% Revenue Growth Recast Arcutis Biotherapeutics' (ARQT) Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601330280","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601330280?lang=en_us&edition=fundamental","pubTime":"2026-01-08 10:45","pubTimestamp":1767840340,"startTime":"0","endTime":"0","summary":"In recent days, Arcutis Biotherapeutics reported revenue growth of about 121.70%, reflecting strong momentum in its dermatology portfolio led by ZORYVE for plaque psoriasis and atopic dermatitis.\nThis rapid expansion in dermatology revenue, alongside supportive analyst sentiment despite ongoing operating losses, highlights how ZORYVE is becoming central to Arcutis’ business profile.\nWe’ll now examine how this very large revenue increase and growing ZORYVE traction may influence Arcutis...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/will-zoryve-driven-1217-revenue-growth-recast-arcutis-biothe","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/will-zoryve-driven-1217-revenue-growth-recast-arcutis-biothe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARQT"],"gpt_icon":0},{"id":"2601823853","title":"Patrick Burnett, Officer, Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601823853","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601823853?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:47","pubTimestamp":1767826038,"startTime":"0","endTime":"0","summary":"Patrick Burnett, an officer of Arcutis Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2bF09v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Patrick Burnett, Officer, Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2601846379","title":"Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601846379","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601846379?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:32","pubTimestamp":1767738756,"startTime":"0","endTime":"0","summary":"Howard G. Welgus, Director, reported a disposal of common shares of Arcutis Biotherapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8gwWyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2592494995","title":"Arcutis Biotherapeutics Chief Medical Officer Patrick Burnett Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592494995","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592494995?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:54","pubTimestamp":1766012066,"startTime":"0","endTime":"0","summary":"Patrick Burnett, an officer of Arcutis Biotherapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL4Dh48z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis Biotherapeutics Chief Medical Officer Patrick Burnett Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2591658516","title":"Assessing Arcutis Biotherapeutics After 99% Rally and DCF Signals Further Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2591658516","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591658516?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:37","pubTimestamp":1765640256,"startTime":"0","endTime":"0","summary":"If you are wondering whether Arcutis Biotherapeutics is still a smart bet after its big run, or if most of the upside is already priced in, you are not alone. That is exactly what we are going to unpack.\nThe stock has pulled back about 7.0% over the last week, but that comes after a sharp 23.8% gain in the past month and a 99.3% rise year to date, with a 128.7% return over the last year that has completely changed how the market looks at this name.\nThose moves have been fueled by a series of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/assessing-arcutis-biotherapeutics-after-99-rally-and-dcf-sig","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/assessing-arcutis-biotherapeutics-after-99-rally-and-dcf-sig","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","ARQT"],"gpt_icon":0},{"id":"2590323341","title":"Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323341","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323341?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:12","pubTimestamp":1765282377,"startTime":"0","endTime":"0","summary":"Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-inc-nasdaqarqt-stock-rockets-28-as-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-inc-nasdaqarqt-stock-rockets-28-as-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","BK4211","PSQ","ARQT","TSYW.SI","BK4139","QID","MNQmain","NQmain","NVIW.SI","ISBC","USJW.SI","QLD","TQQQ","USAW.SI","SQQQ"],"gpt_icon":1},{"id":"2590879360","title":"Arcutis Biotherapeutics Files Initial Beneficial Ownership Statement for Director Amit Munshi","url":"https://stock-news.laohu8.com/highlight/detail?id=2590879360","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590879360?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:01","pubTimestamp":1765242100,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Amit Munshi as the beneficial owner, serving in the role of Director at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4NnhWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2590514365","title":"Amit Munshi Joins Arcutis Board as Bhaskar Chaudhuri Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590514365?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:00","pubTimestamp":1765227609,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. has appointed Amit Munshi to its Board of Directors, effective December 4, 2025. Bhaskar Chaudhuri, PhD, has retired from the Board and will continue as a consultant for the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8YnbFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","SG9999014039.USD","BK4139","LU2095319765.USD","SG9999014013.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","ARQT","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2590365683","title":"Press Release: Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365683","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365683?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:00","pubTimestamp":1765227600,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Dec. 08, 2025  -- Arcutis Biotherapeutics, Inc. , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company.Amit Munshi is a proven biopharmaceutical leader with a track record of transforming companies and driving multibillion-dollar outcomes. Most recently, as president and CEO of Orna Therapeutics LLC, he spearheaded the merger of Orna and ReNAgade Therapeutics LLC, as well as its Series A financing and operational build-out. Previously, as CEO of Arena Pharmaceuticals, Inc., he led a dramatic turnaround, which included revamping the Company's strategy and raising over $900M in equity and $800M in partnerships, and culminated in Pfizer's $6","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4022","BK4139","ARQT"],"gpt_icon":0},{"id":"2588027345","title":"Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588027345","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588027345?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:24","pubTimestamp":1764800649,"startTime":"0","endTime":"0","summary":"Howard G. Welgus, Director at Arcutis Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL9lQbXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2586782142","title":"U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782142?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:58","pubTimestamp":1764334702,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-WilliamsNov 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biogen,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nL4N3X40QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU2023250504.SGD","LU2491050154.USD","LU1720051108.HKD","LU1548497426.USD","SG9999011175.SGD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU0889565916.HKD","LU1861219969.SGD","AKR","LU1988902786.USD","LU1989763690.USD","LU0323240290.USD","BK4533","LU0061475181.USD","ARQT","LU1201861249.SGD","LU0980610538.SGD","DE","LU1064131342.USD","LU2357305700.SGD","GB00BDT5M118.USD","LU1718418525.SGD","SGXZ23171101.USD","IE00B894F039.SGD","BIIB","SHW","LU1989763427.SGD","LU1093756325.SGD","LU2264538146.SGD","BK4109","LU2023250843.SGD","CBT","BK4597","LU2491050071.SGD","BK4532","BK4090","LU0477156953.USD","IE00BD6J9T35.USD","LU1917777945.USD","LU1093756168.USD","BK4152","LU0289739343.SGD","ECVT","BK4588","SG9999002521.SGD","BK4080","LU1861214812.USD"],"gpt_icon":0},{"id":"2586789218","title":"Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $37 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2586789218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586789218?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:32","pubTimestamp":1764329555,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X4097:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2586388293","title":"Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586388293","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586388293?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:55","pubTimestamp":1764194116,"startTime":"0","endTime":"0","summary":"In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $37.00. Ear co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-arcutis-biotherapeutics-arqt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-arcutis-biotherapeutics-arqt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","ARQT"],"gpt_icon":0},{"id":"2586544376","title":"Arcutis Biotherapeutics (ARQT) Is Up 17.5% After FDA Review Accepted for Pediatric ZORYVE Expansion - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586544376","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586544376?lang=en_us&edition=fundamental","pubTime":"2025-11-25 11:15","pubTimestamp":1764040525,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics recently announced that the FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3%, aiming to expand its approved use in treating plaque psoriasis to children aged 2 to 5 years, with a review decision expected by June 29, 2026.\nThis milestone builds on strong product momentum, including multiple industry awards and expanding pediatric studies, signaling wider clinical acceptance and potential for broader market reach in pediatric dermatology.\nWe'll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-is-up-175-after-fda-review-acce","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-is-up-175-after-fda-review-acce","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2586416461","title":"Arcutis Biotherapeutics CEO Todd Watanabe Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586416461","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586416461?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:46","pubTimestamp":1764027967,"startTime":"0","endTime":"0","summary":"Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4x7KYj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Arcutis Biotherapeutics CEO Todd Watanabe Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":-0.1132},{"period":"1month","weight":-0.0772},{"period":"3month","weight":0.3108},{"period":"6month","weight":0.7356},{"period":"1year","weight":0.9392},{"period":"ytd","weight":-0.0778}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.08471},{"month":2,"riseRate":0.833333,"avgChangeRate":0.23515},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027279},{"month":4,"riseRate":0.5,"avgChangeRate":0.042439},{"month":5,"riseRate":0.5,"avgChangeRate":-0.104728},{"month":6,"riseRate":0.833333,"avgChangeRate":0.06903},{"month":7,"riseRate":0.666667,"avgChangeRate":0.023968},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019179},{"month":9,"riseRate":0.5,"avgChangeRate":-0.050429},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.153171}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction